Shanghai Pharma completes acquisition of 10% equity interest

Shanghai Pharmaceuticals Holding Co., Ltd. (HKEX:2607) announced the completion of its acquisition of a 10% equity interest in Shanghai Pharma (SHPL) on April 25, 2025. The acquisition, initially announced in January and March 2025, involved a share transfer agreement with HUTCHMED Investment. Post-acquisition, Shanghai Pharma is now 60% directly and indirectly held by Shanghai Pharmaceuticals, becoming a non-wholly owned subsidiary, and its financial results will be consolidated into the group’s financial statements. The capital commitment and paid-in capital for HUTCHMED Investment is RMB1,145,000, representing a 5% shareholding ratio. Shanghai TCM holds a 50% stake with RMB11,450,000. GP Fund holds 25.1247% (RMB5,753,560) and Zhibaihe Enterprise Management a 9.8753% stake (RMB2,261,440). The Company itself holds 10% (RMB2,290,000).